530 Clinicopathologic features and outcome of patients with microsatellite instable (MSI-H) cancer treated in a Phase I unit

• Carmen Criscitiello,
• Giuseppe Curigliano,
• Stefania Morganti,
• Gloria Pellizzari,
• Paolo Tarantino,
• Carmen Belli,
• Edoardo Crimini,
• Matteo Repetto,
• Angela Esposito,
• Marzia Locatelli,
• Ida Minchella,
• Eleonora Nicolo’,
• Luca Boscolo Bielo,
• Grazia Castellano,
• Pier Paolo Maria Berton Giachetti,
• Gabriele Antonarelli,
• Liliana Ascione,
• Carmine Valenza,
• Beatrice Taurelli Salimbeni

Affiliations

Carmen Criscitiello

2European Institute of Oncology, Milan, Italy

Giuseppe Curigliano

European Institute of Oncology (IEO), IRCCS, Milan, Italy

Stefania Morganti

2European Institute of Oncology, Milan, Italy

Gloria Pellizzari

Infectious Diseases, Department of Diagnostics and Public Health, University of Verona, Verona, Italy

Paolo Tarantino

Division of Early Drug Development for Innovative Therapies, European Institute of Oncology IRCCS, Milano, Lombardia, Italy

Carmen Belli

Division of Early Drug Development, European Institute of Oncology IRCCS, Milan, Italy

Edoardo Crimini

1Universitá Degli Studi Di Milano, Milano, Italy

Matteo Repetto

2European Institute of Oncology, Milan, Italy

Angela Esposito

2European Institute of Oncology, Milan, Italy

Marzia Locatelli

2European Institute of Oncology, Milan, Italy

Ida Minchella

2European Institute of Oncology, Milan, Italy

Eleonora Nicolo’

2European Institute of Oncology, Milan, Italy

Luca Boscolo Bielo

2European Institute of Oncology, Milan, Italy

Grazia Castellano

2European Institute of Oncology, Milan, Italy

Pier Paolo Maria Berton Giachetti

2European Institute of Oncology, Milan, Italy

Gabriele Antonarelli

2European Institute of Oncology, Milan, Italy

Liliana Ascione

2European Institute of Oncology, Milan, Italy

Carmine Valenza

2European Institute of Oncology, Milan, Italy

Beatrice Taurelli Salimbeni

2European Institute of Oncology, Milan, Italy